STAT+: Bladder cancer immunotherapy from CG Oncology reduced risk of tumor recurrence
CG Oncology's bladder cancer immunotherapy reduced risk of tumor recurrence by 68% — results that may change how physicians treat certain patients.
CG Oncology's bladder cancer immunotherapy reduced risk of tumor recurrence by 68% — results that may change how physicians treat certain patients.
comments(0)
5-min edit window · permanent after that